Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yunan Nie

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Seminars in Respiratory and Critical Care Medicine|August 7, 2025
Small-Cell Lung Cancer UpdatesYunan Nie, Anne C Chiang
Cancer Drug Resistance (Alhambra, Calif.)|January 13, 2025
Mechanisms of immunotherapy resistance in small cell lung cancerYunan Nie, Kurt A Schalper, Anne Chiang
Frontiers in Oncology|January 24, 2022
Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous HistologyTejas Patil, Yunan Nie, Dara L Aisner, et al.
Case Reports in Oncology|May 9, 2022
Atraumatic Splenic Rupture due to Chronic Myelomonocytic Leukemia Treated with Partial Splenic Artery EmbolizationYunan Nie, Andrew Kent, Minh Do, et al.
Phytotherapy Research : PTR|September 4, 2023
Acteoside ameliorates learning and memory impairment in APP/PS1 transgenic mice by increasing Aβ degradation and inhibiting tau hyperphosphorylationLi Gao, Dongqing Wang, Jia Ren, et al.
Clinical Lung Cancer|May 28, 2026
High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase InhibitorsYunan Nie, Alyse Staley, Trista K Hinz, et al.
Lung Cancer (Amsterdam, Netherlands)|November 30, 2024
The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutationsTejas Patil, Dexiang Gao, Alexander Watson, et al.
JTO Clinical and Research Reports|September 30, 2021
Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic <i>ROS1</i>-Rearranged Lung CancersNoura J Choudhury, Jaime L Schneider, Tejas Patil, et al.
JTO Clinical and Research Reports|February 16, 2024
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLCTejas Patil, Alyse Staley, Yunan Nie, et al.
Lung Cancer (Amsterdam, Netherlands)|December 10, 2025
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANSBingnan Zhang, Laura Alder, Samuel Rosner, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Seminars in Respiratory and Critical Care Medicine|August 7, 2025
Small-Cell Lung Cancer UpdatesYunan Nie, Anne C Chiang
Cancer Drug Resistance (Alhambra, Calif.)|January 13, 2025
Mechanisms of immunotherapy resistance in small cell lung cancerYunan Nie, Kurt A Schalper, Anne Chiang
Frontiers in Oncology|January 24, 2022
Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous HistologyTejas Patil, Yunan Nie, Dara L Aisner, et al.
Case Reports in Oncology|May 9, 2022
Atraumatic Splenic Rupture due to Chronic Myelomonocytic Leukemia Treated with Partial Splenic Artery EmbolizationYunan Nie, Andrew Kent, Minh Do, et al.
Phytotherapy Research : PTR|September 4, 2023
Acteoside ameliorates learning and memory impairment in APP/PS1 transgenic mice by increasing Aβ degradation and inhibiting tau hyperphosphorylationLi Gao, Dongqing Wang, Jia Ren, et al.
Clinical Lung Cancer|May 28, 2026
High Programmed Death-Ligand 1 Expression is Associated With a Shorter Progression Free Survival in ALK-Rearranged Lung Cancer Patients Treated With First Line Tyrosine Kinase InhibitorsYunan Nie, Alyse Staley, Trista K Hinz, et al.
Lung Cancer (Amsterdam, Netherlands)|November 30, 2024
The efficacy of continuing osimertinib with platinum pemetrexed chemotherapy upon progression in patients with metastatic non-small cell lung cancer harboring sensitizing EGFR mutationsTejas Patil, Dexiang Gao, Alexander Watson, et al.
JTO Clinical and Research Reports|September 30, 2021
Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic <i>ROS1</i>-Rearranged Lung CancersNoura J Choudhury, Jaime L Schneider, Tejas Patil, et al.
JTO Clinical and Research Reports|February 16, 2024
The Efficacy and Safety of Treating Acquired MET Resistance Through Combinations of Parent and MET Tyrosine Kinase Inhibitors in Patients With Metastatic Oncogene-Driven NSCLCTejas Patil, Alyse Staley, Yunan Nie, et al.
Lung Cancer (Amsterdam, Netherlands)|December 10, 2025
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANSBingnan Zhang, Laura Alder, Samuel Rosner, et al.
Pageof 2